Alon Seri-Levy, Sol-Gel Technologies CEO

Bridge­Bio com­pa­ny sells off rare dis­ease can­di­date to Gal­der­ma part­ner

Is­raeli biotech Sol-Gel Tech­nolo­gies an­nounced Fri­day that it got its hands on a rare dis­ease drug can­di­date from Pelle­Pharm for al­most …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.